Trials that use: Cox proportional-hazards model
New to this method? Read the tutorial →
372 results
- Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery: primary endpoint results,…
- IRISComplete statistical analysis of the IRIS trial of pioglitazone versus placebo after stroke or myocardial infarction, including trial design, time-to-event endpoints, Cox modeling, mixed-effects analysis, multiplicity, interim analysis, results, and statistical interpretation.
- JACOBIndependent statistical analysis of A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer: primary endpoint…
- KATE2Independent statistical analysis of A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced…
- Ketamine Patient-Controlled Analgesia for Acute Pain: Complete Statistical AnalysisIndependent statistical analysis of Ketamine Patient-Controlled Analgesia for Acute Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02062879).
- KEYNOTE-054Independent statistical analysis of KEYNOTE-054, a randomized phase 3 trial of pembrolizumab versus placebo after complete resection of high-risk stage III melanoma, including recurrence-free survival, Cox modeling, confidence intervals, and statistical interpretation.
- KEYNOTE-394Independent statistical analysis of KEYNOTE-394, a randomized phase 3 trial of pembrolizumab or placebo with best supportive care in Asian participants with previously treated advanced hepatocellular carcinoma.
- KPL-301 for Subjects With Giant Cell Arteritis: Complete Statistical AnalysisIndependent statistical analysis of KPL-301 for Subjects With Giant Cell Arteritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03827018).
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib: Complete Statistical AnalysisIndependent statistical analysis of LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- LEAP-001Independent statistical analysis of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- LENSIndependent statistical analysis of Lowering Events in Non-proliferative Retinopathy in Scotland: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03439345).
- LIFEComplete statistical analysis of the LIFE Study, a randomized phase 3 trial comparing a physical activity intervention with successful aging in older adults at risk of disability, including the primary mobility-disability endpoint,…
- Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- LUME-Lung 1Complete statistical analysis of LUME-Lung 1, the phase 3 randomized trial of BIBF 1120 plus docetaxel versus placebo plus docetaxel in second-line non-small cell lung cancer, including time-to-event, response, disease-control, quality-of-life, and…
- LUME-Lung 2Independent statistical analysis of LUME-Lung 2, a randomized phase 3 trial of nintedanib plus pemetrexed versus placebo plus pemetrexed in second-line nonsquamous non-small-cell lung cancer, including progression-free survival, overall survival, response, disease…
- LUX-Lung 6Independent statistical analysis of LUX-Lung 6, the randomized phase 3 trial comparing afatinib with gemcitabine-cisplatin chemotherapy in first-line non-small cell lung cancer. Includes progression-free survival, response, overall survival, quality-of-life endpoints, statistical methods,…
- M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- MAGNIFYIndependent statistical analysis of Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- MAHALEIndependent statistical analysis of Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Malignant Pleural Effusion With ZD6474: Complete Statistical AnalysisIndependent statistical analysis of Malignant Pleural Effusion With ZD6474: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00402896).
- MANDALAA detailed statistical analysis of the phase 3 MANDALA trial of budesonide/albuterol metered-dose inhalers versus albuterol in adults and children 4 years of age or older with asthma, including time-to-event, rate, binary,…
- MASTIndependent statistical analysis of MAST Trial: Multi-modal Analgesic Strategies in Trauma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03472469).
- MATINEEAn independent statistical analysis of the phase 3 MATINEE trial of mepolizumab 100 mg versus placebo in COPD with frequent exacerbations and raised eosinophil levels, covering the negative binomial exacerbation-rate analysis, Cox…
- McCAVEIndependent statistical analysis of A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer: primary endpoint results, effect estimate with…
- Methods Project 4: Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of Methods Project 4: Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01867242).
- METROIndependent statistical analysis of Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- MMVAR – Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation: Complete Statistical AnalysisIndependent statistical analysis of MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- MONARCH plusIndependent statistical analysis of A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02763566).
- MORE-CAREIndependent statistical analysis of MOnitoring REsynchronization deviCes and cARdiac patiEnts: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00885677).
- MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01180634).
- Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery: Complete Statistical AnalysisIndependent statistical analysis of Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery: primary endpoint results, effect estimate with confidence…
- NARLALIndependent statistical analysis of Navelbine And Radiotherapy in Locally Advanced Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00887783).
- NefigardIndependent statistical analysis of Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- NeoALTTOIndependent statistical analysis of the phase 3 NeoALTTO trial of lapatinib and trastuzumab in neoplasms of the breast, including pathological complete response, event-free survival, overall survival, landmark analyses, methodology, and interpretation.
- NextCOVEComplete statistical analysis of the phase 3 NextCOVE trial comparing mRNA-1283 with mRNA-1273 for prevention of COVID-19 in participants aged 12 years and older, including non-inferiority methodology, antibody endpoints, COVID-19 efficacy, safety,…
- NIMBUSIndependent statistical analysis of A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple…
- Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1): Complete Statistical AnalysisIndependent statistical analysis of Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NOAHComplete statistical analysis of the NOAH phase 3 trial of edoxaban versus ASA or placebo in patients with atrial high rate episodes, including trial design, time-to-event methodology, primary and secondary results, safety,…
- OlympiADIndependent statistical analysis of Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.: primary endpoint results,…
- ONTARGETAn independent statistical analysis of ONTARGET and its companion trial TRANSCEND: Cox hazard ratios for telmisartan, ramipril and their combination, the non-inferiority margin of 1.13, renal outcomes in diabetic nephropathy, and serious…
- Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: Complete Statistical AnalysisIndependent statistical analysis of Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission: Complete Statistical AnalysisIndependent statistical analysis of OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission: primary endpoint results,…
- OPTIMISEIndependent statistical analysis of Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01775735).
- OPTIMIZEComplete statistical analysis of the OPTIMIZE phase 3 trial of roflumilast dosing as add-on to standard COPD treatment in severe COPD, including trial design, discontinuation endpoints, logistic and Cox regression, adverse events,…
- OptiVol® Care Pathway: Complete Statistical AnalysisIndependent statistical analysis of OptiVol® Care Pathway: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00847288).
- ORCHARRDIndependent statistical analysis of Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma: primary endpoint results, effect estimate with confidence interval,…
- OReOIndependent statistical analysis of A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…